Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report
Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior o...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/6/547 |
| _version_ | 1797532050134138880 |
|---|---|
| author | Nobutaka Kataoka Yusuke Kunimatsu Rei Tsutsumi Nozomi Tani Izumi Sato Mai Tanimura Takayuki Nakano Keiko Tanimura Daishiro Kato Takayuki Takeda |
| author_facet | Nobutaka Kataoka Yusuke Kunimatsu Rei Tsutsumi Nozomi Tani Izumi Sato Mai Tanimura Takayuki Nakano Keiko Tanimura Daishiro Kato Takayuki Takeda |
| author_sort | Nobutaka Kataoka |
| collection | DOAJ |
| description | Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior outcome of bevacizumab-containing chemothrerapy than the standard platinum doublet regimen, and the synergistic effect of bevacizumab with an immune checkpoint inhibitor (ICI). Bevacizumab effectively normalizes vascularization, especially when the vascular bed is damaged by previous treatment. Bevacizumab promotes immunomodulation when used with ICI. We describe a patient with nonsquamous NSCLC who returned 2.5 years after definitive chemoradiotherapy for postoperative locoregional recurrence in the right supraclavicular lymph node. Considering the destroyed vascular bed due to prior chemoradiotherapy, attaining vascular normalization was critical for effective drug delivery. The patient was treated with a bevacizumab-containing chemoimmunotherapy regimen, which resulted in a complete metabolic response. The patient responded well for 23 months and is receiving ongoing treatment. Thus, bevacizumab-containing chemoimmunotherapy could be advantageous in some recurrent cases after chemoradiotherapy. |
| first_indexed | 2024-03-10T10:53:33Z |
| format | Article |
| id | doaj.art-4f857474ddc54fd5b16aced84a1a0a6b |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T10:53:33Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-4f857474ddc54fd5b16aced84a1a0a6b2023-11-21T22:00:22ZengMDPI AGMedicina1010-660X1648-91442021-05-0157654710.3390/medicina57060547Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case ReportNobutaka Kataoka0Yusuke Kunimatsu1Rei Tsutsumi2Nozomi Tani3Izumi Sato4Mai Tanimura5Takayuki Nakano6Keiko Tanimura7Daishiro Kato8Takayuki Takeda9Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Thoracic Surgery, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8031, JapanChemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior outcome of bevacizumab-containing chemothrerapy than the standard platinum doublet regimen, and the synergistic effect of bevacizumab with an immune checkpoint inhibitor (ICI). Bevacizumab effectively normalizes vascularization, especially when the vascular bed is damaged by previous treatment. Bevacizumab promotes immunomodulation when used with ICI. We describe a patient with nonsquamous NSCLC who returned 2.5 years after definitive chemoradiotherapy for postoperative locoregional recurrence in the right supraclavicular lymph node. Considering the destroyed vascular bed due to prior chemoradiotherapy, attaining vascular normalization was critical for effective drug delivery. The patient was treated with a bevacizumab-containing chemoimmunotherapy regimen, which resulted in a complete metabolic response. The patient responded well for 23 months and is receiving ongoing treatment. Thus, bevacizumab-containing chemoimmunotherapy could be advantageous in some recurrent cases after chemoradiotherapy.https://www.mdpi.com/1648-9144/57/6/547bevacizumabchemoimmunotherapychemoradiotherapynon-small-cell lung cancerrecurrence |
| spellingShingle | Nobutaka Kataoka Yusuke Kunimatsu Rei Tsutsumi Nozomi Tani Izumi Sato Mai Tanimura Takayuki Nakano Keiko Tanimura Daishiro Kato Takayuki Takeda Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report Medicina bevacizumab chemoimmunotherapy chemoradiotherapy non-small-cell lung cancer recurrence |
| title | Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report |
| title_full | Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report |
| title_fullStr | Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report |
| title_full_unstemmed | Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report |
| title_short | Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report |
| title_sort | bevacizumab containing chemoimmunotherapy for recurrent non small cell lung cancer after chemoradiotherapy case report |
| topic | bevacizumab chemoimmunotherapy chemoradiotherapy non-small-cell lung cancer recurrence |
| url | https://www.mdpi.com/1648-9144/57/6/547 |
| work_keys_str_mv | AT nobutakakataoka bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT yusukekunimatsu bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT reitsutsumi bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT nozomitani bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT izumisato bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT maitanimura bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT takayukinakano bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT keikotanimura bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT daishirokato bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport AT takayukitakeda bevacizumabcontainingchemoimmunotherapyforrecurrentnonsmallcelllungcancerafterchemoradiotherapycasereport |